Clinuvel Pharmaceuticals Ltd (CLVLY) SPON ADR EACH REPR 10 NPV

Sell:$7.30Buy:$7.30Price unchangedNo change

Prices delayed by at least 15 minutes
Sell:$7.30
Buy:$7.30
Change:Price unchangedNo change
Deal now
Prices delayed by at least 15 minutes
Sell:$7.30
Buy:$7.30
Change:Price unchangedNo change
Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Clinuvel Pharmaceuticals Limited is a specialty pharmaceutical company. It is focused on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening, acute disorders, as well as healthcare solutions for specialized populations. Its lead therapy, SCENESSE (afamelanotide 16mg), is approved for commercial distribution in Europe, the United States of America, Israel, and Australia as the first systemic photoprotective drug for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). It has operations in Europe, Singapore, and the United States of America. It develops and manufactures NEURACTHEL (adrenocorticotropic hormone) in different formulations, to target neurological, endocrinological, and degenerative disorders. Its pharmaceutical product, PRENUMBRA, has been developed, and its use is to be expanded in the clinic from stroke to Parkinson's.

Key people

Jeffrey V. Rosenfeld
Non-Executive Chairman of the Board
Linda Teng
Director of North American Operations
Claire Newstead-Sinclair
Company Secretary
Pearl E. Grimes
Non-Executive Director
Matthew Pringle
Non-Executive Director
Guy Van Dievoet
Non-Executive Director
Karen A. Agersborg
Non-Executive Independent Director
Lachlan Hay
Acting Chief Executive Officer, Chief Operating Officer
Peter Vaughan
Chief Financial Officer
Dennis J. Wright
Vice President - Scientific Affairs
Antonella Colucci
Vice President - Commercial Affairs
Malcolm Bull
Head of Australian Operations and Investor Relations
Azza Hamila
Head of Quality Assurance and Drug Safety
Emilie Rodenburger
Director - Global Clinical Affairs
David Soloman
Head of Regulatory Affairs
Click to see more

Key facts

  • Shares in issue
    50.20m
  • EPIC
    -
  • ISIN
    US1887691038
  • Location
    Australia
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • Market cap
    $0.00
  • Employees
    -
  • Exchange
  • Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.